The NUVISAN Pharmacokinetic Hub

Excellent Center for In-vitro and In-vivo DMPK, Isotope Chemistry and Discovery & Regulatory Bioanalysis.

Including a state oft the art Animal Housing, dedicated Equipment for radioactive Synthesis and sufficient Technologies for Bioanalysis of Small Molecules for Discovery and Development.


Headcount: 53 (42% university graduates)

Lab Capacity: 1.200 m² Space

Animal Housing Capacity: 1.000 m²

Bioanalytical Capacity: 220 m²

Inspections & Authorizations

GLP certified (1990)

AAALAC Accreditation

License to work with radioactivity (14C, 3H) and genetically modified organisms (S1)


Established in 1965 and hold by Merck KGaA for Discovery and Development of DMPK

Acquisition from Merck KGaA in 2016

Today Grafing supports non-clinical in-vitro and in-vivo DMPK with Merck KGaA as partner

Working Fields & Specialties

In-vitro & In-vivo DMPK

Bioanalysis with respect to discovery and GLP bioanalysis with fast turnaround times

Metabolite Profiling and Identification

Radiosynthesis/Isotope Labelling & QWBA

Mass Spectometry with license to handle radioactivity: human mass balance studies can be supported

NUVISAN Service Lines